Literature DB >> 27671057

In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.

Ken B Waites1, Donna M Crabb2, Yang Liu3, Lynn B Duffy2.   

Abstract

In vitro activities of omadacycline, a new aminomethylcycline, were determined for Mycoplasma and Ureaplasma spp. and compared with those of azithromycin, clindamycin, moxifloxacin, tetracycline, and doxycycline. All omadacycline MICs were <2 μg/ml. MIC90s were 0.063 μg/ml for Mycoplasma hominis, 0.25 μg/ml for Mycoplasma pneumoniae, and 2 μg/ml for Ureaplasma spp. Omadacycline had the lowest MIC90 among all drugs tested against M. hominis Omadacycline activity was not affected by macrolide, tetracycline, or fluoroquinolone resistance.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27671057      PMCID: PMC5119036          DOI: 10.1128/AAC.01734-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.

Authors:  Stephen Villano; Judith Steenbergen; Evan Loh
Journal:  Future Microbiol       Date:  2016-08-19       Impact factor: 3.165

Review 2.  Mycoplasmas and ureaplasmas as neonatal pathogens.

Authors:  Ken B Waites; Brenda Katz; Robert L Schelonka
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 3.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

4.  Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.

Authors:  Michael P Draper; S Weir; A Macone; J Donatelli; C A Trieber; S K Tanaka; Stuart B Levy
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

5.  In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.

Authors:  A B Macone; B K Caruso; R G Leahy; J Donatelli; S Weir; M P Draper; S K Tanaka; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

6.  Macrolide-Resistant Mycoplasma pneumoniae, United States.

Authors:  Xiaotian Zheng; Stella Lee; Rangaraj Selvarangan; Xuan Qin; Yi-Wei Tang; Jeffrey Stiles; Tao Hong; Kathleen Todd; Amy E Ratliff; Donna M Crabb; Li Xiao; T Prescott Atkinson; Ken B Waites
Journal:  Emerg Infect Dis       Date:  2015-08       Impact factor: 6.883

  6 in total
  15 in total

1.  In Vitro Activity of Omadacycline against Chlamydia pneumoniae.

Authors:  Stephan A Kohlhoff; Natalia Huerta; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  Omadacycline.

Authors:  Danial E Baker
Journal:  Hosp Pharm       Date:  2019-01-22

Review 3.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

Review 4.  New Horizons in Mycoplasma genitalium Treatment.

Authors:  Catriona S Bradshaw; Jorgen S Jensen; Ken B Waites
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

Review 5.  Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management.

Authors:  Lin Tong; Shumin Huang; Chen Zheng; Yuanyuan Zhang; Zhimin Chen
Journal:  J Clin Med       Date:  2022-05-17       Impact factor: 4.964

Review 6.  Clinical Utility of Lefamulin: If Not Now, When?

Authors:  Nicholas J Mercuro; Michael P Veve
Journal:  Curr Infect Dis Rep       Date:  2020-07-09       Impact factor: 3.725

Review 7.  Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.

Authors:  George G Zhanel; Jenine Esquivel; Sheryl Zelenitsky; Courtney K Lawrence; Heather J Adam; Alyssa Golden; Rachel Hink; Liam Berry; Frank Schweizer; Michael A Zhanel; Denice Bay; Philippe R S Lagacé-Wiens; Andrew J Walkty; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

8.  In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Li Xiao; Lynn B Duffy; Sixto M Leal
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

9.  Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.

Authors:  Mark H Gotfried; Karolyn Horn; Lynne Garrity-Ryan; Stephen Villano; Evan Tzanis; Surya Chitra; Amy Manley; S Ken Tanaka; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

10.  Microbiology and Preclinical Review of Omadacycline.

Authors:  James A Karlowsky; Judith Steenbergen; George G Zhanel
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.